Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
131.71
-1.57 (-1.18%)
Streaming Delayed Price
Updated: 12:47 PM EDT, Jul 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Today 6:57 EDT
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management.
Via
Benzinga
3 Stocks to Buy if There Is No Interest Rate Cut This Year
Today 6:15 EDT
Here are three stocks to buy and hold for steady gains if the Federal Reserve decides against an interest rate cut in 2024.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
July 23, 2024
Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company's U.S. business has struggled with the rise of GLP-1 drugs and...
Via
Benzinga
Britain's Drug Regulator Approves Novo Nordisk's Weight Loss Drug Wegovy To Cut Heart Disease Risk In Obese Patients
July 23, 2024
The U.K. MHRA has approved Novo Nordisk's Wegovy (semaglutide) to prevent cardiovascular issues in overweight and obese adults with existing heart conditions. This new indication highlights Wegovy's...
Via
Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
July 23, 2024
Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road.
Via
The Motley Fool
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
July 19, 2024
Via
Benzinga
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
July 17, 2024
Via
Benzinga
Why Hims & Hers Heath Shares Are Surging Today
July 22, 2024
Hims & Hers Health Inc. (NYSE: HIMS) shares are moving higher on Monday amidst the announcement of Kåre Schultz's appointment to the Board of Directors.
Via
Benzinga
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
July 22, 2024
President Biden's decision to drop out may harm healthcare and create market volatility. Kamala Harris could defend his record and support Medicare for All.
Via
Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
July 22, 2024
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in...
Via
Benzinga
7 Sorry Biotech Stocks Set to Make Investors Sad
July 22, 2024
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell.
Via
InvestorPlace
Here's My Top Growth Stock to Buy Right Now
July 20, 2024
Hims & Hers shares have multi-bagger growth potential over the years to come.
Via
The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
July 20, 2024
They're small now, but these stocks could grow much larger.
Via
The Motley Fool
Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
July 19, 2024
Skyrocketing demand for GLP-1 medications for weight loss is causing shortages, impacting type 2 diabetics. While some insurers are limiting off-label use, government agencies have yet to prioritize...
Via
Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
July 19, 2024
The Nasdaq tumbled amid chip woes.
Via
Investor's Business Daily
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
July 19, 2024
Eli Lilly's Tirzepatide approved by China's NMPA for long-term weight management, targeting adults with specific BMI criteria.
Via
Benzinga
7 A-Rated Stock Picks With Huge Upside Potential
July 19, 2024
We could be headed to a volatile end to the year. The best way to protect yourself is to invest in A-rated stocks like these.
Via
InvestorPlace
Is Viking Therapeutics a Millionaire-Maker?
July 19, 2024
This biotech stock fits the profile of a potentially big winner to a T.
Via
The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
July 18, 2024
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.
Via
Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
July 18, 2024
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
AI Demand and New Deals Make Ginkgo Bioworks Stock a Speculative Buy
July 18, 2024
Ginkgo Bioworks has multiple, positive catalysts that can make the low valuation of Ginkgo Bioworks stock melt up.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio
July 17, 2024
These three wild-card stocks will spice up your portfolio in ways boring diversification never could, so read on.
Via
InvestorPlace
Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
July 17, 2024
Novo Nordisk expresses disappointment over the Dutch Health Care Institute's advice against including Wegovy in the Netherlands' basic insurance, citing unclear health benefits and high costs.
Via
Benzinga
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
July 17, 2024
Roche has a new GLP-1 weight loss drug in the works -- and one very cheap stock.
Via
The Motley Fool
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
July 17, 2024
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On...
Via
Benzinga
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
July 17, 2024
Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest...
Via
Benzinga
Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data
July 17, 2024
Roche released early-stage data on its oral weight-loss drug.
Via
Investor's Business Daily
3 Hot Growth Stocks That Will Make You Forget About AMD
July 16, 2024
There are a number of hot growth stocks out there that can outdo AMD, even after its latest acquisition of Silo AI.
Via
InvestorPlace
Senate To Review Novo Nordisk's Levemir Insulin Discontinuation
July 16, 2024
Novo Nordisk will meet with U.S. Senate aides to discuss the discontinuation of Levemir, its long-acting insulin, amid concerns about manufacturing constraints and patient access. Senators press for...
Via
Benzinga
3 Dow Jones Stocks to Buy at 52-Week Lows in July
July 16, 2024
The Dow Jones has rallied, similar to the other well-known market indices, but not all of its stocks are trading at all-time highs.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.